Chugai Pharmaceutical

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Chugai Pharmaceutical sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).

17 total trials 4 currently recruiting 9 completed early-phase tilt top decile by trial count

Chugai Pharmaceutical: 17 sponsored US clinical trials, 4 recruiting.

Chugai Pharmaceutical sponsors 17 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 9 completed. 0 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Celiac Disease, with 2 trials.

Top-decile sponsor footprint

Chugai Pharmaceutical ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 27/100

9 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

17 total, page 1 of 1

RECRUITING Phase 2

Study of DONQ52 in Active Celiac Disease

NCT07239336
RECRUITING Phase 1

Study of AUBE00 in Patients With Solid Tumors

NCT07030959
RECRUITING Phase 1

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

NCT06371417
RECRUITING Phase 1

A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

NCT05907980
ACTIVE NOT RECRUITING Phase 1

A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

NCT04511845
COMPLETED Phase 1

A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors

NCT05735366
COMPLETED

A Decentralized Home-Based Study To Investigate Novel Objective Biomarker Of Gluten-Mediated Symptoms In Celiac Disease Participants (CeDar ROSE Study)

NCT05686369
COMPLETED Phase 1

Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients

NCT05425446
TERMINATED Phase 1

A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

NCT05012618
TERMINATED Phase 1

A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism

NCT04209179
COMPLETED Phase 1

A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

NCT02965053
COMPLETED Phase 1

A Study of ERY974 in Patient With Advanced Solid Tumors

NCT02748837
TERMINATED Phase 1

A Single Ascending Dose Study of PCO371 in Healthy Volunteers

NCT02475616
COMPLETED Phase 2

A Phase 2 Study of CIM331 for Atopic Dermatitis Patients

NCT01986933
COMPLETED Phase 1

Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

NCT00976170
COMPLETED Phase 1

A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

NCT00746317
COMPLETED Phase 1

Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases

NCT00060138

Phase Distribution

PhaseTrial count
Phase 1 14
Phase 2 2

Therapeutic Areas

Celiac Disease 2
Immune-mediated Necrotizing Myopathy (IMNM) 1
Dermatomyositis (DM) 1
Behçet's Syndrome (BS) 1
Bullous Pemphigoid (BP) 1
Antiphospholipid Syndrome (APS) 1
Locally Advanced or Metastatic Solid Tumors 1
Immune Thrombocytopenia (ITP) 1
Solid Tumors 1
Atopic Dermatitis 1

What is open in the Chugai Pharmaceutical pipeline

4 recruiting of 17 indexed (24% open); 9 completed (53%).

Phase mix: 0 late (III/IV) vs 16 early (I/II) (early-phase heavy).

Top condition: Celiac Disease (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Chugai Pharmaceutical: open-pipeline peers nationwide

Peers matched on 17 registered trials and 24% open enrollment, not the therapeutic-area sidebar.

Chugai Pharmaceutical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1520253035 0%5%10%15%20%25% Total trials Recruiting share Chugai PharmaceuticalAchieve Life SciencesBioDelivery Sciences InternationalConvaTecDurham VA Medical CenterHALEONOncotherapeuticsScripps Whittier Diabetes InstituteThe Mind Research Network
Chugai Pharmaceutical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Chugai Pharmaceutical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 17 trials (± recruiting share)

Sponsors near 24% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Chugai Pharmaceutical page

17 registered trials is a research-attention snapshot, not an endorsement of Chugai Pharmaceutical or any single study.

  • 4 of Chugai Pharmaceutical's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Celiac Disease is the condition Chugai Pharmaceutical studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Celiac Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Chugai Pharmaceutical pipeline card: 17 registered trials from official public datasets.Report a data error.